PATENT CLAIM ANALYSIS

Application Number: 16032655
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "450000"]

Abstract:
The invention concerns compositions comprising: (i) biocompatible hydrogel, comprising a plurality of cross-linkers connecting backbone components of the hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by a matrix metalloproteinase; said inhibitor being effective as a treatment of a condition related to the presence of the matrix metalloproteinase; wherein the hydrogel encapsulates and retains the inhibitor within the intact hydrogel through non-covalent interactions; wherein the hydrogel comprises one or more of hyaluronic acid, sulfated hyaluronic acid, sulfonated hyaluronic acid, dextran, dextran sulfate, sulfonated dextran, chondroitin sulfate, heparin and heparan sulfate; (ii) pentosan polysulfate (PPS) and (iii) optionally, a therapeutic agent comprising an inhibitor of matrix metalloproteinase.

Claim (Index 18):
A process for treating myocardial infarction, osteoarthritis, meniscal repair, ligament repair or treating aortic aneurisms compromising administering to a patient in need of such treatment a composition of  claim 2 .

Metadata:
- Claim Count in Document: 62.0
- Percentile: 95.0
- Lexical Diversity: 1.88
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15628766', '13805501', '14553442', '13508821', '13642078']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.741400839122067
- 35 USC 102 Novelty (BERT): 0.6034203313126373
- Combined Prediction Score: 0.727602788341124
- Mean Citation Score: 393.880322
- Max Citation Score: 591.24194
- Similarity Product: 447.1430829366421

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test